Conjugated Linoleic Acid / Leucine Versus Metformin on Visceral Fat in Metabolic Syndrome
Metabolic Syndrome
About this trial
This is an interventional treatment trial for Metabolic Syndrome focused on measuring Conjugated Linoleic Acid, Leucine, visceral fat area, Epicardial Fat, Hemodinamic Parameters
Eligibility Criteria
Inclusion Criteria:
Diagnosis of metabolic syndrome by IDF criteria:
- Central obesity (defi ned as waist circumference* with ethnicity specifi c values)≥80 cm in females and ≥90 cm in males
plus any two of the following four factors:
- Raised triglycerides ≥ 150 mg/dL (1.7 mmol/L) or specific treatment for this lipid abnormality Reduced HDL colesterol
- < 40 mg/dL (1.03 mmol/L) in males < 50 mg/dL (1.29 mmol/L) in females or specifi c treatment for this lipid abnormality
- Raised blood pressure systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg or treatment of previously diagnosed hypertension
Raised fasting plasma glucose (FPG) ≥ 100 mg/dL (5.6 mmol/L), or previously diagnosed type 2 diabetes
- Stable body weight in the last 3 months
- Written informed consent
Exclusion Criteria:
- Ascitis
- With previous abdominal surgery
- Pathologies that course with abdominal wall edema fluid retention
- Paniculitis of reumatic origin or any other ethiology
- Reumatic pathologies
- Metalic prothesis
- Previous known allergy to any of the ingredients that make up the active treatments assigned
- Known problem of fat absortion, esteatorrea, lipase deficiency, malabsortion of intestinal problems, CUCI
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Active Comparator
Placebo Comparator
Placebo Comparator
cojugated ALC/Leucine+Metformin
Metformin+placebo conjugatedALC/leucine
Placebo of Metformin
ACL/Leu placebo
Intervention with conjugated linoleic acid/Leucine + 500mg in individuals with METS
active comparator with Metformin 500mg + Placebo of ACL/Leucine in individuals with METS
Active comparator with ACL/Leucine + Placebo of Metformin in individuals with METS
Placebo comparator with ACL/Leu placebo + Metformin placebo in individuals with METS